Navigation Links
Positive Outcome of Drug-Drug Interaction Trial With Intravenous Iclaprim
Date:11/21/2007

REINACH, Switzerland, November 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today the results of a Phase I trial investigating the possible interaction between intravenous iclaprim and warfarin. Warfarin is widely used for the prophylaxis of thrombosis and embolism and its dosing needs to be well-controlled.The drug-drug interaction study comprised 24 healthy volunteers and was performed in Germany. Dosing of warfarin with and without pre- and co-administration of iclaprim (1.6 mg/kg infused over 60 minutes) was investigated.

Administration of intravenous iclaprim at this supra-therapeutic dose was assessed to be safe for clinical applications. It had no significant effect on the pharmakonetics and pharmacodynamics of warfarin. Moreover, the trial results again confirm the good safety and tolerability profile of iclaprim.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The results of this Phase I study are very positive, showing that iclaprim has no significant effect on the pharmacokinetics of warfarin, which is widely used in the targeted patient population. The results expand the experience gathered in an earlier Phase I study in which the interaction between ketaconazole and iclaprim was investigated. In summary, iclaprim's drug-drug interaction profile looks favourable. This is of great importance as iclaprim is expected to be administered to patients with significant co-morbidities and receiving several other medications. These Phase I data add substantial weight to the NDA package that we intend to file shortly with the U.S. Food and Drug Administration for intravenous iclaprim in its first indication: complicated Skin and Skins Structure Infections (cSSSI)."

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of
'/>"/>

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
7. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Blood Donations in U.S. Testing Positive for Chagas Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The empty capsules market is experiencing ... and technological innovations in the empty capsules market. ... the growth of the empty capsules market. , ... Scope of Report , The report will enrich ... firms to gauge the pulse of the market ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
(Date:12/17/2014)... Achim Noack has been named global vice ... this position, Noack will assist Jerry Stoller, CEO and ... strategy and supervise global marketing management and implementation of ... knowledge and experience in the crop protection industry,” says ... innovative thinking will be a great asset for Stoller ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... June 5, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) today ... of financing arrangements, including a $3 million investment already ... further funding on fixed, specified and favorable terms, at ... chooses.  This series of financing arrangements will provide a ...
... Recent biopharmaceutical product launches have produced both noteworthy failures ... with a continually evolving launch landscape, organizations are rethinking ... current launch environment. In a new ... and failure points facing new product launches, Best Practices, ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... financial results for the fourth quarter and full year of ... close in the US.   The Company will ... June 13, 2011 to discuss its financial performance and give ...
Cached Biology Technology:Northwest Biotherapeutics Announces Series of Financing Arrangements 2Northwest Biotherapeutics Announces Series of Financing Arrangements 3Northwest Biotherapeutics Announces Series of Financing Arrangements 4Creating a Road Map for Successful Cardiovascular New Product Launch 2China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Austin researchers have discovered how to extract and use information ... from the focus distance, a feat only accomplished by human ... camera, the human eye has an auto-focusing system, but human ... not require trial and error to focus an object. ...
... Texas Advanced Computing Center (TACC) at the University of ... and support a world-class supercomputer with comprehensive computing and ... Made possible by a $27.5 million grant from the ... of the NSF "eXtreme Digital" (XD) program, an integrating ...
... some people with asthma do not respond well to inhaled ... Researchers found that asthma patients who have two copies of ... steroid inhalers as those with two copies of the regular ... National Heart, Lung, and Blood Institute (NHLBI), part of the ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4NIH-funded study connects gene variant to response to asthma drugs 2
Anti Human S14G-Humanin Polyclonal Antibody...
... a positive control for ChIP assays. Efficient ... vivo is a crucial step for the ... is probably the most important parameter. Two ... should be taken into account: first, an ...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Biology Products: